Creating A Sustainable Business Model For Cell And Gene Therapies

Stock-market weakness during 2022 and early 2023, as central banks have raised rates to combat inflation, has put pressure on startups to deliver results. In the biomedical field, innovators need to think more carefully about their strategies for developing and commercializing new therapies. The path to success for businesses involved in cell and gene therapy is not without challenges. Unlike other areas of pharmaceuticals, in this field 90% of companies are still trying to launch their first product.

To examine how the development of cell and gene therapies can be made a sustainable business, Economist Impact facilitated a roundtable discussion, supported by AmerisourceBergen, as part of the Cell and Gene Therapy Summit 2023. Participants included senior staff in the biopharmaceutical industry, clinicians, academics and researchers, and members of patient-advocacy organizations.